세계의 소아마비 백신 시장

Global Polio Vaccines Market to Reach US$979.2 Million by 2030

The global market for Polio Vaccines estimated at US$809.0 Million in the year 2024, is expected to reach US$979.2 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Inactivated Polio Vaccine, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$624.0 Million by the end of the analysis period. Growth in the Oral Polio Vaccine segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$220.4 Million While China is Forecast to Grow at 5.9% CAGR

The Polio Vaccines market in the U.S. is estimated at US$220.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$192.1 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Polio Vaccines Market - Key Trends & Drivers Summarized

Why Do Polio Vaccines Remain a Cornerstone of Global Public Health Despite Near-Eradication?

Polio vaccines have been the foundation of one of the most ambitious global public health campaigns ever undertaken-aiming to eliminate poliomyelitis, a crippling and potentially fatal infectious disease caused by the poliovirus. Despite significant progress, with wild poliovirus now endemic in only a few countries, continued vaccination remains critical due to risks of re-emergence, vaccine-derived poliovirus strains, and global mobility. Two primary vaccine types-oral polio vaccine (OPV) and inactivated polio vaccine (IPV)-remain central to immunization strategies in different regions depending on transmission risk, healthcare infrastructure, and regulatory frameworks.

OPV, particularly the bivalent (bOPV) and novel oral polio vaccine type 2 (nOPV2), is widely used in mass immunization campaigns due to its ease of administration and ability to confer community protection through gut immunity and viral shedding. IPV, on the other hand, is preferred in high-income countries and in routine immunization schedules for its safety profile and lack of risk for vaccine-derived strains. As the global health community transitions to a polio endgame strategy, the co-administration of IPV and nOPV2 is being prioritized to ensure immunity, prevent outbreaks, and achieve long-term eradication.

How Are Technological Advancements and Strategic Formulations Enhancing Vaccine Efficacy and Safety?

Vaccine R&D has evolved to develop safer and more stable polio vaccines with improved immunogenicity and a lower risk of circulating vaccine-derived poliovirus (cVDPV). The introduction of nOPV2, engineered with genetically stabilized attenuation profiles, represents a breakthrough in addressing the challenges posed by type 2 poliovirus outbreaks linked to earlier OPV formulations. This vaccine is being deployed under WHO’s Emergency Use Listing and has shown promising early field results in limiting the emergence of neurovirulent revertants.

Advances in cold chain logistics, freeze-drying, and prefilled injectable formats have further expanded the reach and shelf life of polio vaccines, particularly in remote or conflict-affected regions. Combination vaccines incorporating IPV with diphtheria, pertussis, and tetanus (DPT-IPV) are gaining traction in routine immunization programs for their efficiency and broader coverage. The use of digital immunization registries, barcoded vials, and geospatial mapping in immunization campaigns is also improving traceability, monitoring, and data-driven deployment, thereby enhancing vaccination efficacy and accountability.

Which Global Alliances and Regional Programs Are Driving Polio Vaccine Distribution and Coverage?

The Global Polio Eradication Initiative (GPEI)-led by WHO, UNICEF, the U.S. CDC, Rotary International, and the Bill & Melinda Gates Foundation-has been the primary driver of vaccine funding, coordination, and field deployment for over three decades. National immunization days (NIDs), door-to-door campaigns, and outbreak response immunization efforts (ORIs) have all played pivotal roles in raising global polio vaccine coverage. Countries with weak health infrastructure or conflict zones remain priority areas, requiring targeted campaigns and cross-border coordination.

South Asia and sub-Saharan Africa have historically been focal points for vaccine delivery, although most regions have now transitioned from trivalent OPV (tOPV) to bOPV and IPV. Afghanistan and Pakistan remain the last strongholds of wild poliovirus, necessitating ongoing surveillance and high-frequency immunization drives. In developed regions such as North America and Europe, IPV is standard in national immunization schedules, with focus now shifting to bolstering preparedness and maintaining herd immunity. As global eradication inches closer, regional surveillance and sustained vaccine uptake will be essential to prevent resurgence.

What Is Driving Long-Term Strategic Focus and Innovation in the Polio Vaccines Market?

The growth in the polio vaccines market is driven by ongoing global eradication efforts, emergence of cVDPV outbreaks, and international health security mandates. While eradication may ultimately reduce the size of the routine polio vaccine market, short- to medium-term demand is expected to remain high due to emergency responses, transition plans, and stockpile requirements. Governments and NGOs are committed to maintaining high coverage and vaccine stockpiles to ensure polio’s irreversible elimination.

Strategically, manufacturers are investing in next-generation IPV production using Vero cell and Sabin strain platforms to increase biosafety and reduce production costs. Technology transfers and local manufacturing initiatives-especially in India, Indonesia, and parts of Africa-are enhancing regional supply chain resilience. Public-private partnerships, pooled procurement by UNICEF and Gavi, and continued innovation in vaccine packaging and delivery are reinforcing the global vaccination infrastructure. As the polio endgame approaches, the vaccine market will pivot from volume-based supply to a strategic reserve-driven, precision-deployment model aimed at complete and sustained eradication.

SCOPE OF STUDY:

The report analyzes the Polio Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Inactivated Polio Vaccine, Oral Polio Vaccine); End-Use (Hospitals & Clinics End-Use, Public Services End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Adithya Vaccine Pharma
• Astellas Pharma Inc.
• Beijing Tiantan Biological Products Corp
• Bharat Biotech International Ltd.
• Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL)
• Bio Farma
• Bio-Med Healthcare Products Pvt. Ltd.
• Biomed-Lublin
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline (GSK)
• Haffkine Bio-Pharmaceutical Corporation Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Polio Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Conducive Government Policies and Polio Eradication Activities Drive Vaccine Demand
  • Technological Innovations Enhance Vaccine Development and Distribution Efficiency
  • Increase in Infant Population and Immunization Programs Supports Market Growth
  • Global Health Initiatives and Partnerships Strengthen Vaccination Campaigns
  • Emergence of Combination Vaccines Simplifies Immunization Schedules
  • Advancements in Cold Chain Logistics Improve Vaccine Storage and Transportation
  • Expansion of Routine Immunization Programs in Developing Countries Boosts Coverage
  • Regulatory Approvals and WHO Prequalification Facilitate Market Entry of New Vaccines
  • Investment in Research and Development Accelerates Introduction of Novel Formulations
  • Public Awareness Campaigns and Education Initiatives Increase Vaccine Acceptance
  • Integration of Digital Health Records Enhances Tracking and Monitoring of Immunization
  • Challenges in Vaccine Hesitancy and Misinformation Necessitate Targeted Communication Strategies
  • Development of Oral Polio Vaccines (OPV) and Inactivated Polio Vaccines (IPV) Offers Diverse Options
  • Strategic Collaborations Between Governments and Pharmaceutical Companies Strengthen Supply Chains
  • Focus on Cost-Effective Manufacturing Processes Improves Affordability and Accessibility
  • Implementation of Surveillance Systems Aids in Early Detection and Response to Outbreaks
  • Expansion into Emerging Markets Presents Opportunities for Market Penetration
  • Continuous Monitoring and Evaluation of Vaccine Efficacy Ensures Public Health Safety
  • Adoption of Innovative Delivery Methods Enhances Immunization Coverage
  • Ongoing Efforts Toward Global Polio Eradication Sustain Long-Term Market Demand
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Polio Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Polio Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Polio Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Polio Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Inactivated Polio Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Inactivated Polio Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Inactivated Polio Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Oral Polio Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Oral Polio Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Oral Polio Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Public Services End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Public Services End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Public Services End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: USA 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 23: USA Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: USA 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Canada Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: Canada 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: Canada 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Japan Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: Japan 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: Japan 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 38: China Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: China Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: China 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 41: China Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: China 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 44: Europe Recent Past, Current & Future Analysis for Polio Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: Europe Historic Review for Polio Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Europe 15-Year Perspective for Polio Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Europe 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Europe 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 53: France Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: France Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: France 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 56: France Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: France 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 59: Germany Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Germany Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Germany 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Germany 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 65: Italy Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Italy Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Italy 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Italy 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 71: UK Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: UK Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: UK 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 74: UK Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: UK 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 77: Spain Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Spain Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Spain 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Spain 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 83: Russia Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Russia Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Russia 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Russia 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Rest of Europe Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Rest of Europe 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Rest of Europe 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Polio Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 96: Asia-Pacific Historic Review for Polio Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Asia-Pacific 15-Year Perspective for Polio Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Asia-Pacific 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 104: Australia Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Australia Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Australia 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 107: Australia Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Australia Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Australia 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 110: India Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: India Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: India 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 113: India Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: India Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: India 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 116: South Korea Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: South Korea Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: South Korea 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 119: South Korea Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: South Korea Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: South Korea 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Rest of Asia-Pacific Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Rest of Asia-Pacific Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 128: Latin America Recent Past, Current & Future Analysis for Polio Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 129: Latin America Historic Review for Polio Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Latin America 15-Year Perspective for Polio Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 131: Latin America Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Latin America Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Latin America 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Latin America 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 137: Argentina Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Argentina Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Argentina 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 140: Argentina Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Argentina Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Argentina 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 143: Brazil Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Brazil Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Brazil 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 146: Brazil Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Brazil Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Brazil 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 149: Mexico Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Mexico Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Mexico 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 152: Mexico Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Mexico Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Mexico 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Latin America Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Latin America 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Latin America Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Latin America 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 161: Middle East Recent Past, Current & Future Analysis for Polio Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 162: Middle East Historic Review for Polio Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Middle East 15-Year Perspective for Polio Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 164: Middle East Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Middle East Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Middle East 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Middle East 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 170: Iran Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Iran Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Iran 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 173: Iran Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Iran Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Iran 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 176: Israel Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Israel Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Israel 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 179: Israel Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Israel Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Israel 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Saudi Arabia Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Saudi Arabia 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Saudi Arabia Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Saudi Arabia 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 188: UAE Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: UAE Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: UAE 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 191: UAE Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: UAE Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: UAE 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Middle East Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Middle East 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Middle East Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Middle East 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 200: Africa Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Africa Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Africa 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
  • TABLE 203: Africa Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Africa Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Africa 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION